Uncovering the anti-cancer mechanisms of Immuno-Oncology

GNTbm-CC-01 is the first new drug combination of tumor microenvironment regulator developed by GNTbm.  The drug combination consists of a novel epigenetic modulator chidamide and a generic drug C. The anti-cancer mechanisms of GNTbm-CC-01 primarily involve the activation of immune response. It selectively inhibits cell growth and differentiation of progenitor cells from the bone marrow, which are further differentiated into monocytes and M-MDSCs (monocytic myeloid-derived suppressor cells).  The reduction in the numbers of monocytes and M-MDSCs can be clearly detected in the blood circulation after treatment with GNTbm-CC-01. 

In the tumor microenvironment, GNTbm-CC-01 significantly reduces the tumor-infiltrating Treg cells (regulatory T cells), Besides, we also found both numbers of tumor-infiltrating PMN-MDSCs (polymorphonuclear myeloid-derived suppressor cells) and M-MDSCs were significantly decreased. On the other hand, the large number of TAMs (tumor-associated macrophages) also significantly declined. However, the numbers of tumor-infiltrating CD4+T cells and CD8+T cells were not significantly changed.

GNTbm-CC-01 has potent anti-cancer immune response activity, mainly reduces the number and function of many immunosuppressive cells and activates the activity of CD8+T cells and NK cells to kill tumors. It will eventually produces memory T cells, effectively surveilling and killing cancer cells expressing the same antigen for T cell recognition, and therefore producing permanent immune activity. The combination of GNTbm-CC-01 with immune checkpoint inhibitor will further enhance the anti-cancer effect and boost the immune response rate.

GNTbm-CC-01 patent has been submitted to 23 regions or countries.

Figure 1. Anti-cancer mechanisms of GNTbm-CC-01